At the intersection of endomyocardial biopsy and dd-cfDNA, where do we go?

Read full text Summarise with VIRAT
Authors: Gregory A. Fishbein, Marc K. Halushka
Cited by: 0
References: 35

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cardiac allograft rejection has traditionally been assessed by endomyocardial biopsy (EMB). Blood-based assays such as donor-derived cell-free DNA (dd-cfDNA) are increasingly used, yet emerging data highlight discordance between these approaches. This review evaluates recent data, examines causes of disagreement, and suggests strategies to better align EMB and dd-cfDNA.

Fields of Study & Subjects

Transplantation: Methods and Outcomes Renal Transplantation Outcomes and Treatments Organ and Tissue Transplantation Research

Publication details

Journal / source
Cardiovascular Pathology
Volume
83
Pages
107825–107825
Publication date
28 March 2026
Language
EN